MetaCap

Aardvark Therapeutics (AARD) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Vicore Pharma AB is the larger company by market cap ($246.4 million vs $105.4 million), about 2.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-17.20%VCRE-46.71%
+36%-7%-51%
Jul 6, 20261 yearOct 7, 2026
AARD-34.74%VCRE-37.16%
+6%-17%-39%
Jul 6, 20265 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus VCRE key metrics
MetricAARDVCRE
Share price$4.82$8.75
Market cap$105.38M$246.44M
1-day change-2.92%+1.04%
YTD return-62.21%—
1-year return-71.51%—
EPS (TTM)$-3.21$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$17.23$17.80
52-week low$3.35$7.88
Distance from 52-week high-72.05%-50.84%
Analyst consensus—none
Avg. price target upside—+278.97%
Average volume209.46K16.24K
Shares outstanding21.88M28.16M
Employees—46
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Vicore Pharma AB is about 2.3 times larger than Aardvark Therapeutics by market value ($246.44M vs $105.38M).

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees

AARD vs VCRE FAQ

Which is bigger, Aardvark Therapeutics or Vicore Pharma AB?

Vicore Pharma AB (VCRE) is larger, with a market capitalization of $246.44M compared with $105.38M for Aardvark Therapeutics (AARD).

Are Aardvark Therapeutics and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons